Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
Spruce Biosciences appointed Adrian Quartel, M.D., FFPM, as Chief Medical Officer, leveraging his 25 years of experience in launching enzyme replacement therapies for rare diseases. The hire comes at a critical time as Spruce prepares for a BLA filing of its lead candidate TA-ERT for Sanfilippo Syndrome Type B in Q4 2026. As an inducement award, Dr.
Key figures
- Rsu grant
- 13000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.